# Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00025285** · PHASE2 · COMPLETED · sponsor: **Wake Forest University Health Sciences** · enrollment: 46 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** irinotecan hydrochloride
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00025285
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11-01
- **Primary completion:** 2004-09-29
- **Final completion:** 2004-09-29
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2021-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00025285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00025285, "Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00025285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*